To translate our findings into clinical trials, high CD44v expression in gastric cancer tissues could be utilised as criteria to select patients to be enrolled in the EGFR-targeted therapy in combination with the cytotoxic antitumor agent. The gene discussed is EGFR; the disease is gastric cancer.